All posts by: Michael Zand

About Michael Zand

Why CRISPR Therapeutics AG Stock Is Rising Today – Motley Fool

Continue reading

2018-01-05 NEWS

Nasdaq

Why CRISPR Therapeutics AG Stock Is Rising Today
Motley Fool
Specifically, the company announced a underwritten public offering of 5,000,000 of its common shares at a public offering price of $22.75 per share before the start of today’s session. Under normal circumstances, a secondary offering that equates to a
CRISPR Therapeutics Announces Pricing of Public Offering of Common SharesGlobeNewswire (press release)
Tyler Dylan-Hyde Sells 15000 Shares of Crispr Therapeutics AG (CRSP) StockThe Ledger Gazette
CRISPR Therapeutics Announces Proposed Public Offering of Common SharesNasdaq
CNA Finance (press release) –Post Analyst –Simply Wall St
all 69 news articles »
Continue reading

2018-01-05 NEWS

OncLive

Frontline Immunotherapy in Advanced Bladder Cancer
OncLive
Daniel J. George, MD: For our patients who are, say, cisplatin-ineligible but maybe aren’t quite as symptomatic, maybe then I’m more concerned about their long-term tolerance to chemotherapy. I’m worried about maybe some other complications associated

and more »